Intrexon Corp (NYSE:XON) insider Nir Nimrodi sold 4,058 shares of the stock in a transaction on Thursday, January 3rd. The stock was sold at an average price of $7.07, for a total value of $28,690.06. Following the completion of the sale, the insider now owns 9,766 shares of the company’s stock, valued at approximately $69,045.62. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Intrexon stock opened at $7.82 on Monday. Intrexon Corp has a twelve month low of $6.21 and a twelve month high of $20.16.
Intrexon (NYSE:XON) last posted its earnings results on Thursday, November 8th. The biotechnology company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.21). The business had revenue of $32.45 million during the quarter, compared to the consensus estimate of $35.98 million. The firm’s revenue for the quarter was down 29.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.33) EPS.
Several hedge funds have recently modified their holdings of XON. Rhumbline Advisers increased its position in shares of Intrexon by 13.0% during the second quarter. Rhumbline Advisers now owns 67,537 shares of the biotechnology company’s stock worth $941,000 after purchasing an additional 7,784 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Intrexon by 18.4% during the second quarter. Bank of New York Mellon Corp now owns 278,611 shares of the biotechnology company’s stock worth $3,884,000 after purchasing an additional 43,310 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Intrexon by 68.2% during the second quarter. Schwab Charles Investment Management Inc. now owns 355,075 shares of the biotechnology company’s stock worth $4,950,000 after purchasing an additional 143,993 shares in the last quarter. Swiss National Bank increased its position in shares of Intrexon by 13.6% during the second quarter. Swiss National Bank now owns 122,100 shares of the biotechnology company’s stock worth $1,702,000 after purchasing an additional 14,600 shares in the last quarter. Finally, BlackRock Inc. increased its position in shares of Intrexon by 76.8% during the second quarter. BlackRock Inc. now owns 4,647,554 shares of the biotechnology company’s stock worth $64,788,000 after purchasing an additional 2,019,142 shares in the last quarter. 84.92% of the stock is currently owned by institutional investors and hedge funds.
Intrexon Company Profile
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.
Further Reading: Technical Analysis of Stocks and What It Means
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.